Long-term Liver-related Outcomes of Patients with Chronic Liver Diseases in Australia

• Published in: Clinical gastroenterology and hepatology Vol. 18; no. 2; pp. 496 - 504.e3
• Main Authors: Huang, Yi, Joseph, John, de Boer, W. Bastiaan, Cheng, Wendy, Adams, Leon A, MacQuillan, Gerry, Garas, George, Raftopoulos, Spiro, Jeffrey, Gary P
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-02-2020
• Subjects: ALD; Cirrhosis; Gastroenterology and Hepatology; HCC; Survival; MRF; NAFLD; ICD-10; HACO; hepatitis B virus; HR; SVR; PBC; autoimmune hepatitis; hepatitis C virus; AID; HBV; hepatocellular carcinoma; AIH; PSC; International Statistical Classification of Diseases and Health-related Problems, 10th Revision; OS; CI; HCC; Hepascore and clinical outcome; WADLU; Survival; autoimmune liver disease without overlap; Cirrhosis; alcoholic liver disease; metabolic risk factors; nonalcoholic fatty liver disease; Western Australia Data Linkage Unit; hazard ratio; ALD; sustained viral response; confidence interval; HCV; autoimmune overlap syndrome; primary biliary cholangitis; primary sclerosing cholangitis
• ISSN: 1542-3565; 1542-7714
• DOI: 10.1016/j.cgh.2019.07.013

Background & AimsChronic liver disease is a major health burden that produces significant liver-related morbidity and mortality. We aimed to evaluate liver-related outcomes of patients with different causes of chronic liver disease in Australia. MethodsWe collected data from 10,933 patients with chronic liver disease assessed by Hepascore (a serum fibrosis model) in Western Australia from 2004 through 2015. We obtained records of liver-related death, transplantation, decompensation, and hepatocellular carcinoma from WA Data Linkage Unit databases. Competing risk analysis was used to calculate the cumulative risk of each clinical endpoint, and risks for clinical endpoints were compared among all causes of chronic liver disease. ResultsIn our final cohort for analysis, 5566 patients had hepatitis C virus (HCV) infection, 1989 had HBV infection, 119 were infected with HBV and HCV, 955 had alcohol-associated liver disease, 1597 had non-alcoholic fatty liver disease (NAFLD), 123 had alcohol-associated liver disease and metabolic risk factors, 561 had autoimmune liver disease without overlap syndrome, and 23 autoimmune overlap syndrome. Significant differences among chronic liver diseases were observed in risk of all-cause death ( P < .001), liver-related death ( P < .001), liver transplantation ( P < .001), and decompensation ( P < .001) but not hepatocellular carcinoma ( P=.095). Patients with alcohol-associated liver disease had the highest 5-year cumulative risk of liver-related death (17.1%) and the second-highest 5-year cumulative risk of decompensation (29.2%). Multivariate analysis found patients with alcohol-associated liver disease had significantly higher risks of liver-related death and decompensation than patients with HCV infection with hazard ratios (HRs) of 2.39 (95% CI, 1.88–3.03) and 3.42 (95% CI, 2.74–4.27), respectively. Patients with NAFLD had a significantly lower risk of liver related death and decompensation than patients with HCV infection, with HRs of 0.67 (95% CI, 0.48–0.95) and 0.70 (95% CI, 0.52–0.94) respectively. ConclusionsIn an analysis of patients in Western Australia, we found patients with alcohol-associated liver disease to have significantly higher risk of decompensation and liver-related death than patients with HCV infection, whereas patients with NAFLD have significantly lower risks of either outcome.